Tempus AI shares rose 11% in premarket trading after reporting preliminary 2025 revenue of $1.27 billion, up 83% year-over-year, and record total contract value exceeding $1.1 billion.
TechStock² 2026-01-12
TE
Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. The company operates one of the world's largest libraries of multimodal clinical and molecular data with an AI-enabled operating system.
Combines one of the world's largest libraries of clinical and molecular data with AI to enable precision medicine solutions for both patient care and drug discovery
Analytics General
Content: Data
Pricing: Subscription
Security & Compliance
SOC 2 No evidence found
GDPR No evidence found
HIPAA No evidence found
No Training Commitment No evidence found
Traction Signals
LinkedIn Followers 119.3K
Total Funding $1.3B
Latest Round Debt Financing
Team Size ~750
Company Info
Target Audience
Healthcare providers, pharmaceutical companies, biotechnology companies, and academic research centers
Headquarters USA
Founded 2015
Use Cases
- • genomic profiling
- • clinical trial matching
- • drug discovery and development
- • companion diagnostics
- • care gap identification
Recent News
Tempus announced record total contract value of over $1.1 billion and signed data agreements with over 70 customers including major pharmaceutical companies like AstraZeneca, Pfizer, Merck, and Novartis.
Business Wire 2026-01-11
Known Customers
Pfizer Verified
Abbvie Verified
Boehringer Ingelheim Verified
Merck Verified
GlaxoSmithKline Verified
Classification Rationale
Tempus uses AI to analyze genomic and clinical data for personalized medicine, particularly in oncology, and to accelerate research.